- Home
- ANIK vs ACIU Comparison
ANIK vs ACIU Comparison
Compare ANIK & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANIK
- ACIU
- Stock Information
- Founded
- ANIK 1983
- ACIU 2003
- Country
- ANIK United States
- ACIU Switzerland
- Employees
- ANIK N/A
- ACIU N/A
- Industry
- ANIK Medical/Dental Instruments
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- ANIK Health Care
- ACIU Health Care
- Exchange
- ANIK Nasdaq
- ACIU Nasdaq
- Market Cap
- ANIK 196.6M
- ACIU 173.7M
- IPO Year
- ANIK 1993
- ACIU 2016
- Fundamental
- Price
- ANIK $12.39
- ACIU $1.63
- Analyst Decision
- ANIK Buy
- ACIU Strong Buy
- Analyst Count
- ANIK 2
- ACIU 2
- Target Price
- ANIK $21.50
- ACIU $10.00
- AVG Volume (30 Days)
- ANIK 62.4K
- ACIU 134.3K
- Earning Date
- ANIK 05-09-2025
- ACIU 04-30-2025
- Dividend Yield
- ANIK N/A
- ACIU N/A
- EPS Growth
- ANIK N/A
- ACIU N/A
- EPS
- ANIK N/A
- ACIU N/A
- Revenue
- ANIK $117,053,000.00
- ACIU $32,014,254.00
- Revenue This Year
- ANIK N/A
- ACIU N/A
- Revenue Next Year
- ANIK $8.65
- ACIU $676.94
- P/E Ratio
- ANIK N/A
- ACIU N/A
- Revenue Growth
- ANIK 4.61
- ACIU 91.20
- 52 Week Low
- ANIK $12.83
- ACIU $1.43
- 52 Week High
- ANIK $29.12
- ACIU $4.98
- Technical
- Relative Strength Index (RSI)
- ANIK 29.84
- ACIU 42.79
- Support Level
- ANIK $11.48
- ACIU $1.55
- Resistance Level
- ANIK $15.04
- ACIU $1.79
- Average True Range (ATR)
- ANIK 0.61
- ACIU 0.11
- MACD
- ANIK -0.24
- ACIU 0.02
- Stochastic Oscillator
- ANIK 8.77
- ACIU 48.39
About ANIK Anika Therapeutics Inc.
Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States and also has its presence in Europe and Other countries.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.